Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
- Greinacher A.
- Selleng K.
- Mayerle J.
- Palankar R.
- Wesche J.
- Reiche S.
- Aebischer A.
- Warkentin T. E.
- Muenchhoff M.
- Hellmuth J. C.
- Keppler O. T.
- Duerschmied D.
- Lother A.
- Rieg S.
- Gawaz M. P.
- Mueller K. A. L.
- Scheer C. S.
- Napp M.
- Hahnenkamp K.
- Lucchese G.
- Vogelgesang A.
- Floel A.
- Lovreglio P.
- Stufano A.
- Marschalek R.
- Thiele T.
DOIAbstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associated with unusual thrombosis. VITT is caused by anti-platelet factor 4 (PF4) antibodies activating platelets through their FcγRIIa receptors. Antibodies that activate platelets through FcγRIIa receptors have also been identified in patients with COVID-19. These findings raise concern that vaccination-induced antibodies against anti-SARS-CoV-2 spike protein cause thrombosis by cross-reacting with PF4. Immunogenic epitopes of PF4 and SARS-CoV-2 spike protein were compared using in silico prediction tools and 3D modeling. The SARS-CoV-2 spike protein and P...
Add to ORKG